Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

NCT02679963 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

180

Enrollment

OTHER

Sponsor class

Stopped study design, change of standard of care, enrollment difficulties

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Olaparib
DRUG: Placebo

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris